Safety of propranolol tablets for infantile hemangioma

doi:10.19803/j.1672-8629.2022.07.11

Abstract

Abstract: Objective To analyze the risk of propranolol tablets in the treatment of infantile hemangioma so as to provide reference for clinical rational drug use. Methods The reports about adverse drug reactions (ADR) induced by propranolol tablets for infantile hemangioma that were collected in China adverse drug reaction database from January 1, 2004 to July 10, 2020 and those collected in WHO Vigilyze, CNKI, VIP and Wanfang database from inception to December 1, 2020 were retrieved and analyzed, while related domestic and foreign drug Instructions were also reviewed. Results Treatment of infantile hemangioma with propranolol tablets was off-label, and children were vulnerable to the risk of serious adverse reactions such as hypoglycemia and sleep disturbance. Conclusion It is recommended that medical institutions should carry out physical examinations and screening for children before prescribing this drug and monitor blood pressure and heart rate during medication. Drug manufacturers should make more effort to monitor adverse reactions of their products, improve the information on safety in drug inserts in time, and ensure the safety of patients' medication.

Key words: propranolol, hemangioma, adverse drug reaction, regulatory measure, infantile, hypoglycemia, sleep disturbance

CLC Number:

MENG Kangkang, WANG Chunting, XIONG Weiyi. Safety of propranolol tablets for infantile hemangioma[J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 749-751.

Add to citation manager EndNote|Ris|BibTeX

URL: https://zgywjj.magtechjournal.com/EN/10.19803/j.1672-8629.2022.07.11

https://zgywjj.magtechjournal.com/EN/Y2022/V19/I7/749

References

[1] LIU WY.Consensus on propranolol treatment for infantile hemangiomas[J]. Chinese Journal of Pediatric Surgery(中华小儿外科杂志), 2019, 40(10): 865-869.
[2] FDA. Drugs@FDA: FDA-Approved Drugs[EB/OL].[2022-04-02]. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205410.
[3] European Medicines Agency.Hemangiol [EB/OL].[2022-04-02].https://www.ema.europa.eu/en/medicines/human/EPAR/hemangiol#product-information-section.
[4] National Medical Products Administration. Domestic Drugs - Basic Information of "National Drug Approval Word H20213648"[EB/OL].[2022-04-02]. https://www.nmpa.gov.cn/datasearch/search-info.html?nmpa=aWQ9MTg4ODQxJml0ZW1JZD1mZjgwODA4MTdjODMxMmM0MDE3YzliYmZjOGRlMDM2MA==.
[5] National Medical Products Administration. Data Query-Domestic Drugs-Propranolol Oral Solution[EB/OL].(2020-10-26)[2022-04-02]. https://www.nmpa.gov.cn/datasearch/search-result.html.
[6] BURKEY BW, JACOBS JA, AZIZ H.Temperature instability in an infant treated with propranolol for infantile hemangioma[J]. Journal of Pediatric Pharmacology & Therapeutics, 2017, 22(2): 124.
[7] ZHANG KS, MA L, ZHANG X.Propranolol hydrochloride-induced infantile allergic proctocolitis[J]. Adverse Drug Reactions Journal(药物不良反应杂志), 2018, 20(6): 2.
[8] YU L, LI L, MA L.Short- and long-term safety of oral propranolol in the treatment of infantile hemangioma[J]. Chinese Journal of Dermatology(中华皮肤科杂志), 2019, 52(8): 586-589.
[9] ZHU GRN, LI P, LI JH, et al.Study on adverse reactions to oral propranolol in the first week treatment of infantile hemangiomas[J]. Journal of Diagnosis and Therapy on Dermato-venereology(皮肤性病诊疗学杂志), 2019, 26(3): 138-143.
[10] CHEN QL, QIAN QF, YANG Y, et al.Propranolol for medium and high risk infantile hemangiomas: a 3-year retrospective study[J]. Journal of Diagnosis and Therapy on Dermato-venereology(皮肤性病诊疗学杂志), 2018, 25(6): 344-349.
[11] WANG CH, SU ZM, LIN WX.Analysis of the complications in patients with infantile hemangiomas treated by oral Propranolol[J]. Chinese Journal of Aesthetic Medicine(中国美容医学), 2016, 25(1): 54-56.
[12] LIU HJ, TAO C, HUANG HJ.Study of mechanism of diarrhea resulted from oral propranolol treatment of infantile hemangioma[J]. Chongqing Medicine(重庆医学), 2016, 45(32): 4514-4516.
[13] Uppsala Monitoring Centre. Vigilyze[EB/OL].(2020-12-20)[2022-04-02]. https://vigilyze.who-umc.org/.
[14] NMPA. National Medical Products Administration Announcement on the Revision of the Package Insert of the Propranolol Tablets (No. 94 in2021) [EB/OL]. (2021-07-20) [2022-01-28]. https://www.nmpa.gov.cn/xxgk/ggtg/ypshmshxdgg/20210720155539168.html.
[15] MA L, WANG H, LI L, et al.Chinese expert consensus on β-blockers for the treatment of infantile hemangioma[J]. Chinese Journal of Dermatology(中华皮肤科杂志), 2020, 53(7): 493-500.
[16] ZHENG JW, WANG XK, QIN ZP.Chinese experts consensus on the use of oral propranolol for treatment of infantile hemangiomas[J]. Shanghai Journal of Stomatology(上海口腔医学), 2016, 25(3): 257-260.